Germany
Japan
United Kingdom
China
Dystonin (DST) human monoclonal antibody, clone H5E.Hy.4B
| Applications | IF, IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
Antibodies
View as table DownloadDystonin (DST) human monoclonal antibody, clone H10D-Hy-8B
| Applications | IF, IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
CD49b (ITGA2) human monoclonal antibody, clone B4F12
| Applications | FC, IF |
| Reactivities | Human |
| Conjugation | Alexa Fluor 488 |
CD49b (ITGA2) human monoclonal antibody, clone B4F12
| Applications | FC, IF |
| Reactivities | Human |
| Conjugation | Alexa Fluor 647 |
Recombinant Anti-c-myc epitope tag (Clone 9E10)
| Applications | IF, IHC, IP, WB |
| Conjugation | Unconjugated |
Recombinant Anti-c-myc epitope tag (Clone 9E10)
| Applications | IF, IHC, IP, WB |
| Conjugation | His Tag |
Recombinant Anti-c-myc epitope tag (Clone 9E10)
| Applications | IF, IHC, IP, WB |
| Conjugation | Unconjugated |
Recombinant Anti-c-myc epitope tag (Clone 9E10)
| Applications | IF, IHC, IP, WB |
| Conjugation | Unconjugated |
Recombinant Anti-c-myc epitope tag (Clone 9E10)
| Applications | IF, IHC, IP, WB |
| Conjugation | Unconjugated |
Recombinant Anti-V5 epitope tag (Clone SV5-P-K)
| Applications | ELISA, IF, IHC, IP, WB |
| Conjugation | Unconjugated |
Recombinant Anti-V5 epitope tag (Clone SV5-P-K)
| Applications | ELISA, IF, IHC, IP, WB |
| Conjugation | His Tag |
Recombinant Anti-V5 epitope tag (Clone SV5-P-K)
| Applications | ELISA, IF, IHC, IP, WB |
| Conjugation | Unconjugated |
Recombinant Anti-V5 epitope tag (Clone SV5-P-K)
| Applications | ELISA, IF, IHC, IP, WB |
| Conjugation | Unconjugated |
Recombinant Anti-V5 epitope tag (Clone SV5-P-K)
| Applications | ELISA, IF, IHC, IP, WB |
| Conjugation | Unconjugated |
Recombinant Anti-TRP-1, gp75 (Clone TA99)
| Applications | ELISA, FC, IF, IHC, IP, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. |
USD 523.00
2 Weeks
Recombinant Anti-IL-2R alpha (CD25) (Clone Basiliximab)
| Applications | FC, IF, IHC, WB |
| Reactivities | Human, Monkey |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-CD33 (Clone hP67.6 (Gemtuzumab))
| Applications | FC, IF |
| Reactivities | Human |
| Conjugation | Unconjugated |
Recombinant Anti-Human Ephrin Type A receptor 2 (Clone 1C1)
| Applications | ELISA, FC, IF, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
USD 523.00
2 Weeks
Recombinant Anti-alpha 5 beta 1 Integrin (Clone M200 (Volociximab))
| Applications | ELISA, FC, IF, IHC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Recombinant Anti-TNF alpha (Clone D2E7 (Adalimumab))
| Applications | ELISA, IF, IHC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Recombinant Anti-desmosome/hemidesmosome (Clone F12)
| Applications | IF |
| Reactivities | Human |
| Conjugation | Unconjugated |
Recombinant Anti-COVID-19 & SARS-CoV S glycoprotein (Clone CR3022)
| Applications | ELISA, IF |
| Conjugation | Unconjugated |
Recombinant Anti-COVID-19 & SARS-CoV S glycoprotein (Clone CR3022)
| Applications | ELISA, IF |
| Conjugation | Unconjugated |
| Modifications | This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-COVID-19 & SARS-CoV S glycoprotein (Clone CR3022)
| Applications | ELISA, IF |
| Conjugation | Unconjugated |
| Modifications | This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
USD 523.00
2 Weeks
Recombinant Anti-Covid-19 & SARS-CoV Nucleoprotein (Clone CR3018 (03-018))
| Applications | ELISA, IF |
| Reactivities | SARS-CoV |
| Conjugation | Unconjugated |
USD 675.00
2 Weeks
Recombinant Anti-Covid-19 & SARS-CoV Nucleoprotein (Clone CR3018 (03-018))
| Applications | ELISA, IF |
| Reactivities | SARS-CoV |
| Conjugation | Unconjugated |
| Modifications | This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
USD 675.00
2 Weeks
Recombinant Anti-Covid-19 & SARS-CoV Nucleoprotein (Clone CR3018 (03-018))
| Applications | ELISA, IF |
| Reactivities | SARS-CoV |
| Conjugation | Unconjugated |
| Modifications | This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
USD 523.00
2 Weeks
Recombinant Anti-Covid-19 & SARS-CoV Nucleoprotein (Clone CR3009 (03-009))
| Applications | ELISA, IF |
| Reactivities | SARS-CoV |
| Conjugation | Unconjugated |
USD 675.00
2 Weeks
Recombinant Anti-Covid-19 & SARS-CoV Nucleoprotein (Clone CR3009 (03-009))
| Applications | ELISA, IF |
| Reactivities | SARS-CoV |
| Conjugation | Unconjugated |
| Modifications | This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
USD 675.00
2 Weeks
Recombinant Anti-Covid-19 & SARS-CoV Nucleoprotein (Clone CR3009 (03-009))
| Applications | ELISA, IF |
| Reactivities | SARS-CoV |
| Conjugation | Unconjugated |
| Modifications | This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-BRD4 (Clone RAB-C131)
| Applications | ChIP, ELISA, FC, IF |
| Reactivities | Human |
| Conjugation | His Tag |
Recombinant Anti-CBX1 (Clone RAB-C145)
| Applications | ChIP, ELISA, IF |
| Reactivities | Human |
| Conjugation | His Tag |
Recombinant Anti-PRMT5 (Clone RAB-C136)
| Applications | ChIP, ELISA, IF |
| Reactivities | Human |
| Conjugation | His Tag |
Recombinant Anti-WDR5 (Clone RAB-C223)
| Applications | ChIP, ELISA, FC, IF |
| Reactivities | Human |
| Conjugation | His Tag |
Recombinant Anti-CBX2 (Clone RAB-C238)
| Applications | ChIP, ELISA, IF |
| Reactivities | Human |
| Conjugation | His Tag |
Recombinant Anti-L3MBTL1 (Clone RAB-C213)
| Applications | ChIP, ELISA, FC, IF |
| Reactivities | Human |
| Conjugation | His Tag |
Recombinant Anti-PRDM4 (Clone RAB-C367)
| Applications | ChIP, ELISA, IF |
| Reactivities | Human |
| Conjugation | His Tag |
Recombinant Anti-PRDM9 (Clone RAB-C370)
| Applications | ChIP, ELISA, IF |
| Reactivities | Human |
| Conjugation | His Tag |
Active filters
Applications
- IF
Antibody Hosts
- Human
Filter by
Target Symbol
Reactivities
Isotypes
Clonalities
Conjugates
Modifications
- This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (6)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (1)